About Karyon Bio
Harnessing the power of AI to revolutionize liver health.
Harnessing the power of AI to revolutionize liver health.
Founded in the heart of Silicon Valley (Mountain View, California), Karyon Bio was born out of a deep commitment to tackling one of the most pressing health challenges of our time — metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD).
In simple terms, MASLD refers to the buildup of excess fat in the liver in people who drink little to no alcohol. It affects a staggering 30% of the global population, and its symptoms often go undetected until they progress to advanced stages — leading to severe complications such as cirrhosis, liver failure, and liver cancer.
When combined with metabolic dysfunctions, the morbidity associated with MASLD increases exponentially, making early diagnosis and effective management critical.
Karyon Bio is building the next generation of agentic artificial intelligence (AI) healthcare solutions that transform how complex diseases like MASLD are detected, understood, and managed. Partnering globally with hospitals, genome institutes, and research labs, our pioneering AI-driven approach empowers clinicians, researchers, and ultimately patients to achieve desired results faster and more efficiently than ever before.
It's a bold claim — which is why we encourage you to contact us and discover for yourself why the future is here today with Karyon Bio.